



Gp/1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Charles T. Esmon and Jun Xu

Serial No.: 09/139,425

Art Unit: 1643

MAR 15 2000

Filed: August 25, 1998

Examiner: W. Sandals

TECH CENTER 1600/2900

For: *TARGETING OF MOLECULES TO LARGE VESSEL
ENDOTHELIUM USING PCR*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, copies of the documents cited therein, and a copy of the International Search Report, mailed 09 February 2000, in the corresponding PCT application PCT/US99/19480.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

U.S.S.N.: 09/139,425
Filed: August 25, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

MAR 15 2000

TECH CENTER 1600/2900


Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 318 201 A2	05-31-1989	Scripps Clinic and Research Foundation	EP
0 687 687 A2	12-20-1995	Immuno Aktiengesellschaft Industriestrasse	EP
WO 89/02747 A1	04-06-1989	The American National Red Cross	PCT
WO 90/08556 A1	08-09-1990	Baxter International Inc.	PCT
WO 98/55142 A1	12-10-1998	Eli Lilly and Company	PCT
WO 99/00673 A1	01-07-1999	Oklahoma Medical Research Foundation	PCT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,


Kevin W. King
Reg. No. 42,737

Dated: March 6, 2000


ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 W. Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8596
(404) 873-8597 (fax)

U.S.S.N.: 09/139,425
Filed: August 25, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: March 6, 2000


Julie Tennyson